Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 5, 2011, Pages

  Castillero, Estíbaliz ^a   Nieto Bona, María Paz ^b   Fernández Galaz, Carmen ^a   Martín, Ana Isabel ^a   López Menduiña, María ^a   Granado, Miriam ^c   Villanúa, María Angeles ^a   López Calderón, Asunción ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Atrogin 1; Muscle RING finger 1; Peroxisome proliferator activated receptor a

Indexed keywords

ATROGIN 1; CYCLINE; FENOFIBRATE; MUSCLE RING FINGER 1 PROTEIN; MYOD PROTEIN; MYOGENIN; MYOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEASOME; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FAST MUSCLE FIBER; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; LIPID BLOOD LEVEL; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SKELETAL MUSCLE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ATROPHY; BODY WEIGHT; EATING; FENOFIBRATE; GENE EXPRESSION; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOGENIC REGULATORY FACTORS; MYOSTATIN; ORGAN SIZE; PPAR GAMMA; RATS; RATS, WISTAR; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

EID: 79955569162     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00590.2010     Document Type: Article

References (58)

1. Allen DL, Bandstra ER, Harrison BC, Thorng S, Stodieck LS, Kostenuik PJ, Morony S, Lacey DL, Hammond TG, Leinwand LL, Argraves WS, Bateman TA, Barth JL. Effects of spaceflight on murine skeletal muscle gene expression. J Appl Physiol 106: 582-595, 2009.
2. Allen DL, Cleary AS, Lindsay SF, Loh AS, Reed JM. Myostatin expression is increased by food deprivation in a muscle-specific manner and contributes to muscle atrophy during prolonged food deprivation in mice. J Appl Physiol 109: 692-701, 2010.
3. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol Endocrinol Metab 268: E996-E1006, 1995.
4. Baraka A, Abdel Gawad H. Targeting apoptosis in the heart of streptozotocin- induced diabetic rats. J Cardiovasc Pharmacol Ther 15: 175-181, 2010.
5. Benedini-Elias PC, Morgan MC, Gomes AR, Mattiello-Sverzut AC. Changes in postnatal skeletal muscle development induced by alternative immobilization model in female rat. Anat Sci Int 84: 218-225, 2009.
6. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
7. Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 10: 675-682, 2004.
8. Cantini M, Massimino ML, Rapizzi E, Rossini K, Catani C, Dalla Libera L, Carraro U. Human satellite cell proliferation in vitro is regulated by autocrine secretion of IL-6 stimulated by a soluble factor(s) released by activated monocytes. Biochem Biophys Res Commun 216: 49-53, 1995.
9. Carvalho RF, Castan EP, Coelho CA, Lopes FS, Almeida FL, Michelin A, de Souza RW, Araújo JP Jr, Cicogna AC, Dal Pai-Silva M. Heart failure increases atrogin-1 and MuRF1 gene expression in skeletal muscle with fiber type-specific atrophy. J Mol Histol 41: 81-87, 2010.
10. Castillero E, Martín AI, López-Menduiña M, Granado M, Villanúa MA, López-Calderón A. IGF-I system, atrogenes and myogenic regulatory factors in arthritis induced muscle wasting. Mol Cell Endocrinol 309: 8-16, 2009.
11. Castillero E, Martín AI, López-Menduiña M, Villanúa MA, López-Calderón A. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors. Am J Physiol Regul Integr Comp Physiol 297: R1322-R1331, 2009.
12. Chen SE, Jin B, Li YP. TNF-_ regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 292: C1660-C1671, 2007.
13. Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Dunn C, Everitt JI, Voss KA, Swanson C, Kimbrough C, Wong JS, Gill SS, Chandraratna RA, Kwak MK, Kensler TW, Stulnig TM, Steffensen KR, Gustafsson JA, Mehendale HM. Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J Biol Chem 279: 46204-46212, 2004.
14. Crossland H, Constantin-Teodosiu D, Gardiner SM, Constantin D, Greenhaff PL. A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol 586: 5589-5600, 2008.
15. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275: 36703-36707, 2000.
16. Doucet M, Russell AP, Léger B, Debigaré R, Joanisse DR, Caron MA, LeBlanc P, Maltais F. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 261-269, 2007.
17. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 27: 793-799, 2008.
18. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doerrler W, Dinarello CA, Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 33: 1765-1776, 1992.
19. Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 286: E201-E207, 2004.
20. Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res 49: 2179-2187, 2008.
21. Fernandez AZ. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res 2008: 285842, 2008.
22. Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor- {alpha} agonists in autoimmune disease. J Immunol 182: 4479-4487, 2009.
23. Goto M. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 20: 238-243, 2010.
24. Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. Am J Physiol Endocrinol Metab 289: E1007-E1014, 2005.
25. Granado M, Martín AI, Villanúa MA, López-Calderón A. Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol Endocrinol Metab 292: E1656-E1665, 2007.
26. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71: 343S-348S, 2000.
27. Ji Y, Wang Z, Li Z, Liu J. Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 25: 631-640, 2010.
28. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169-1196, 2004.
29. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10: 530-534, 2004.
30. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
31. López-Menduiña M, Martín AI, Castillero E, Villanúa MA, López-Calderón A. Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3. Am J Physiol Regul Integr Comp Physiol 299: R541-R551, 2010.
32. Ma K, Mallidis C, Artaza J, Taylor W, Gonzalez-Cadavid N, Bhasin S. Characterization of 5=-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab 281: E1128-E1136, 2001.
33. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 36: 345-349, 1998.
34. Martín AI, Castillero E, Granado M, López-Menduiña M, Villanúa MA, López-Calderón A. Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis. J Endocrinol 197: 111-119, 2008.
35. Massimino ML, Rapizzi E, Cantini M, Libera LD, Mazzoleni F, Arslan P, Carraro U. ED2 macrophages increase selectively myoblast proliferation in muscle cultures. Biochem Biophys Res Commun 235: 754-759, 1997.
36. Mazzucotelli A, Viguerie N, Tiraby C, Annicotte JS, Mairal A, Klimcakova E, Lepin E, Delmar P, Dejean S, Tavernier G, Lefort C, Hidalgo J, Pineau T, Fajas L, Clément K, Langin D. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes. Diabetes 56: 2467-2475, 2007.
37. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 209: 501-514, 2006.
38. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109: 595-601, 2002.
39. Michalik L, Wahli W. PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res 2008: 134059, 2008.
40. Moylan JS, Smith JD, Chambers MA, McLoughlin TJ, Reid MB. TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am J Physiol Cell Physiol 295: C986-C993, 2008.
41. Novak ML, Billich W, Smith SM, Sukhija KB, McLoughlin TJ, Hornberger TA, Koh TJ. COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. Am J Physiol Regul Integr Comp Physiol 296: R1132-R1139, 2009.
42. Okada M, Inoue Y, Ube M, Sano F, Ikeda I, Sugimoto J, Takagi S. Skeletal muscle susceptibility to clofibrate induction of lesions in rats. Toxicol Pathol 35: 517-520, 2007.
43. Okamoto H, Kamatani N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis 63: 1002-1003, 2004.
44. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23: 323-330, 2005.
45. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptorgamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 52: 869-881, 2008.
46. Otto A, Patel K. Signalling and the control of skeletal muscle size. Exp Cell Res 316: 3059-3066, 2010.
47. Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, Schols AM. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 30: 245-252, 2007.
48. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103: 16260-16265, 2006.
49. Soto L, Martín AI, Vara E, López-Calderón A. Cyclosporin a treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis. Horm Metab Res 33: 590-595, 2001.
50. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21: 495-505, 2002.
51. Smith IJ, Aversa Z, Alamdari N, Petkova V, Hasselgren PO. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle. J Cell Biochem 111: 1059-1073, 2010.
52. Summers GD, Deighton CM, Rennie MJ, Booth AH. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47: 1124-1131, 2008.
53. Suzuki ST, Zhao B, Yang J. Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-alpha, and PPAR-gamma expressions. Biochem Biophys Res Commun 369: 767-773, 2008.
54. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9: 10, 2009.
55. Tiao G, Lieberman M, Fischer JE, Hasselgren PO. Intracellular regulation of protein degradation during sepsis is different in fast- and slow-twitch muscle. Am J Physiol Regul Integr Comp Physiol 272: R849-R856, 1997.
56. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20: 1868-1876, 2000.
57. Zheng B, Ohkawa S, Li H, Roberts-Wilson TK, Price SR. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/ MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J 24: 2660-2669, 2010.
58. Zhu X, Hadhazy M, Wehling M, Tidball JG, McNally EM. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474: 71-75, 2000.